• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 10-K/A filed by ASP Isotopes Inc.

    7/1/24 4:24:46 PM ET
    $ASPI
    Major Chemicals
    Industrials
    Get the next $ASPI alert in real time by email
    aspi_10ka.htm
    0001921865true--12-31FY2023false00019218652023-01-012023-12-3100019218652024-04-0800019218652023-06-30iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 10-K/A

    (Amendment No. 2)

     

    ☒

    ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the year ended December 31, 2023

     

    OR

     

    ☐

    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the transition period from                    to

     

    Commission File Number 001-39069

     

    ASP Isotopes Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware

     

    87-2618235

    (State or other jurisdiction of incorporation or organization)

     

    (I.R.S. Employer Identification No.)

     

     

     

    1101 Pennsylvania Avenue NW, Suite 300

     

    Washington, DC

     

    20004

    (Address of principal executive offices)

     

    (Zip code) 

     

    (202) 756-2245

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name, former address and former fiscal year, if changed since last report)

     

    Securities registered pursuant to Section 12(b) of the Act:

     

     

     

     

     

    Name of exchange

    Title of each class

     

    Trading Symbol

     

    on which registered:

    Common stock, par value $0.01 per share

     

    ASPI

     

    The Nasdaq Capital Market LLC

     

    Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐     No ☒

     

    Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐     No ☒

     

    Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒     No ☐

     

    Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes ☒     No ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated Filer

    ☒

    Smaller reporting company

    ☒

     

     

    Emerging growth company

    ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

    Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

     

    If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

     

    Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

     

    Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐      No ☒

     

    The aggregate market value of the voting stock held by non-affiliates of the registrant as of June 30, 2023 (the last business day of the registrant’s most recently completed second fiscal quarter) was approximately $10.2 million.

     

    There were 48,923,276 shares of the registrant’s common stock, $0.01 par value, outstanding as of April 8, 2024.

     

     

     

     

    EXPLANATORY NOTE

     

    ASP Isotopes Inc. (“ASP Isotopes,” the “Company,” “we,” “us,” or “our”) is filing this Amendment No. 2 on Form 10-K/A (this “Amendment No.2”) to our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, originally filed with the Securities and Exchange Commission (the “SEC”) on April 10, 2024 (the “Original Filing”), as amended by Amendment No.1 thereto filed with the SEC on April 29, 2024 (“Amendment No.1”), to amend and restate Part II “Item 9A: Controls and Procedures” solely to revise Management’s Annual Report on Internal Controls Over Financial Reporting in order to correct a typographical error to state that, based on management’s evaluation, the Company’s internal control over financial reporting was not effective as of the end of the period covered by the Original Filing due to the material weaknesses previously disclosed in the Original Filing.

     

    This Amendment No.2 contains only an updated cover page, this explanatory note, the complete text of Item 9A, the exhibit list, a signature page and the certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

     

    Except as described above, this Amendment No.2 does not amend any other information set forth in the Original Filing, and the Company has not updated disclosures included therein to reflect any subsequent events. Accordingly, this Amendment No.2 should be read in conjunction with our Original Filing, Amendment No.1 and with our other filings with the SEC subsequent to the Original Filing.

     

     
    2

     

      

    Item 9A. Controls and Procedures

     

    Disclosure Controls and Procedures

     

    Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2023. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, mean controls and other procedures of a company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company on the reports that it files or submits under the Exchange Act is accumulated and communicated to management, including, our principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure.

     

    Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgement in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2023, our Chief Executive Officer and Chief Financial Officer concluded that, as a result of a material weakness identified in our internal control over financial reporting, our disclosure controls and procedures were not effective as of December 31, 2023.

     

    In the course of preparing the financial statements that are included in this Form 10-K, management has determined that a material weakness exists within the internal controls over financial reporting. The material weakness identified relates to the lack of formal control documentation and consistent execution of control procedures, and the lack of a sufficient complement of personnel within the finance and accounting function with an appropriate degree of knowledge, experience and training. We also noted a material weakness related to logical security and privileged access in the area of information technology. We concluded that the material weaknesses in our internal control over financial reporting information technology occurred because, prior to becoming a public company, we were a private company and did not have the necessary business processes, systems, personnel, and related internal controls necessary to satisfy the accounting and financial reporting requirements of a public company.

     

    In order to remediate the material weaknesses, we expect to enhance our formal documentation over internal control procedures and management controls infrastructure to allow for more consistent execution of control procedures and hire additional accounting, and finance and information technology resources or consultants with public company experience.

     

    We may not be able to fully remediate the identified material weakness until the steps described above have been completed and our internal controls have been operating effectively for a sufficient period of time. We believe we have already and will continue to make progress in our remediation plan during the year ending December 31, 2023, but cannot assure you that we will be able to fully remediate the material weakness in 2024. If the steps we take do not correct the material weakness in a timely manner, we will be unable to conclude that we maintain effective internal control over financial reporting. Accordingly, there could continue to be a reasonable possibility that a material misstatement of our financial statements would not be prevented or detected on a timely basis. We also may incur significant costs to execute various aspects of our remediation plan but cannot provide a reasonable estimate of such costs at this time.

     

    Management’s Annual Report on Internal Controls Over Financial Reporting

     

    Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act). Our internal control system was designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes, in accordance with generally accepted accounting principles in the United States. Due to inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness of the internal control over financial reporting to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with policies and procedures may deteriorate. Our management, under the supervision and with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our internal control over financial reporting as of the end of the period covered by this Annual Report on Form 10-K based on the framework in Internal Control---Integrated Framework (2013 framework) issued by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO. Based on such evaluation, our management concluded that our internal control over financial reporting was not effective as of the end of the period covered by this Annual Report on Form 10-K due to the material weaknesses described above.

     

     
    3

     

     

    This Annual Report on Form 10-K does not include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. Our auditors will not be required to opine on the effectiveness of our internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002 until we are no longer an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012.

     

    Changes in Internal Control Over Financial Reporting

     

    There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

     

     
    4

     

     

    PART IV

     

    Item 15.  Exhibits, Financial Statement Schedules

     

    The following documents are filed or furnished as part of this Form 10K/A:

     

    (a) Financial Statements

     

    The information concerning our consolidated financial statements and Report of Independent Registered Public Accounting Firm (PCAOB ID 274; Iselin, New Jersey) required by this Item is set forth in Item 8 of the Original Filing, entitled “Financial Statements and Supplementary Data.”

     

    (b) Financial Statement Schedules

     

    All schedules have been omitted because the required information is not present or not present in amounts sufficient to require submission of the schedules, or because the information required is included in the Financial Statements or notes thereto.

     

     
    5

     

     

    (c) Exhibits

     

    Exhibit

     

     

    Number

     

    Description of Document

    3.1**

     

    Amended and Restated Certificate of Incorporation.

     

     

     

    3.2**

     

    Amended and Restated Bylaws.

     

     

     

    4.1**

     

    Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934.

     

     

     

    4.2**

     

    Common Stock Purchase Warrant dated March 17, 2023.

     

     

     

    4.3**

     

    Placement Agent Common Stock Purchase Warrant dated March 17, 2023.

     

     

     

    10.1+**

     

    ASP Isotopes Inc. 2021 Stock Incentive Plan, as amended, and form of award agreements thereunder (incorporated by reference to Exhibit 10.1 to the Form S-1/A filed on November 9, 2022 (File No. 333-267392)).

     

     

     

    10.2+**

     

    ASP Isotopes Inc. 2022 Equity Incentive Plan and form of award agreements thereunder (incorporated by reference to Exhibit 10.2 to the Form S-1/A filed on November 9, 2022 (File No. 333-267392))

     

     

     

    10.3+**

     

    Performance Share Award Grant Notice and Performance Share Award Agreement with Paul Mann, dated October 4, 2021, as amended (incorporated by reference to Exhibit 10.3 to the Form S-1/A filed on November 9, 2022 (File No. 333-267392)).

     

     

     

    10.4+**

     

    Form of Indemnification Agreement between the registrant and each of its directors and executive officers (incorporated by reference to Exhibit 10.4 to the Form S-1/A filed on November 9, 2022 (File No. 333-267392)).

     

     

     

    10.5+**

     

    Form of Director Agreement (incorporated by reference to Exhibit 10.5 to the Form S-1/A filed on November 9, 2022 (File No. 333-267392)).

     

     

     

    10.6+**

     

    Executive Employment Agreement by and between the registrant and Paul Mann, dated October 4, 2021 (incorporated by reference to Exhibit 10.6 to the Form S-1/A filed on November 9, 2022 (File No. 333-267392)).

     

     

     

    10.7+**

     

    Executive Employment Agreement by and between ASP Isotopes Guernsey Limited and Hendrik Strydom, dated January 19, 2022 (incorporated by reference to Exhibit 10.7 to the Form S-1/A filed on November 9, 2022 (File No. 333-267392)).

     

     

     

    10.8+**

     

    Executive Employment Agreement by and between ASP Isotopes Guernsey Limited and Robert Ainscow, dated October 4, 2021, as amended (incorporated by reference to Exhibit 10.8 to the Form S-1/A filed on November 9, 2022 (File No. 333-267392)).

     

     

     

    10.9**

     

    Advisory Agreement by and between the registrant and ChemBridges LLC, dated October 27, 2021, as amended (incorporated by reference to Exhibit 10.9 to the Form S-1/A filed on November 9, 2022 (File No. 333-267392)).

     

     

     

    10.10**

     

    License Agreement between ASP Isotopes South Africa (Proprietary) Limited (formerly PDS Photonica Holdings South Africa (Proprietary) Limited) and Klydon (Proprietary) Limited dated September 30, 2021, as amended (incorporated by reference to Exhibit 10.10 to the Form S-1/A filed on November 9, 2022 (File No. 333-267392)).

     

     

     

    10.11**

     

    License Agreement between ASP Isotopes South Africa (Proprietary) Limited and Klydon (Proprietary) Limited dated January 25, 2021 (incorporated by reference to Exhibit 10.11 to the Form S-1/A filed on November 9, 2022 (File No. 333-267392)).

     

     

     

    10.12**

     

    Contract for a Turnkey Molybdenum Enrichment Plan between ASP Isotopes South Africa (Proprietary) Limited (formerly PDS Photonica Holdings South Africa (Proprietary) Limited) and Klydon (Proprietary) Limited dated November 1, 2021 (incorporated by reference to Exhibit 10.12 to the Form S-1/A filed on November 9, 2022 (File No. 333-267392)).

     

     

     

    10.13**

     

    Letter Agreements between the registrant and Dr Einar Ronander and Dr Hendrik Strydom, dated January 2021 (incorporated by reference to Exhibit 10.13 to the Form S-1/A filed on November 9, 2022 (File No. 333-267392)).

     

     

     

    10.14**

     

    Chief Scientific Adviser Agreement between the registrant and Dr Einar Ronander, dated January 2021 (incorporated by reference to Exhibit 10.14 to the Form S-1/A filed on November 9, 2022 (File No. 333-267392)).

     

     

     

    10.15**

     

    Lease for Molybdenum Processing Plant between ASP Isotopes South Africa (Proprietary) Limited (formerly PDS Photonica Holdings South Africa (Proprietary) Limited) and Morgan Creek Properties 311 Pty Ltd. (incorporated by reference to Exhibit 10.15 to the Form S-1/A filed on November 9, 2022 (File No. 333-267392)).

     

     

     

    10.16**

     

    Form of Subscription Agreement (incorporated by reference to Exhibit 10.16 to the Form S-1/A filed on November 9, 2022 (File No. 333-267392)).

     

     

     

    10.17**

     

    License Agreement between ASP Isotopes UK Ltd and Klydon (Proprietary) Limited dated July 26, 2022 (incorporated by reference to Exhibit 10.17 to the Form S-1/A filed on November 9, 2022 (File No. 333-267392)).

     

     
    6

     

     

     

    Exhibit

     

     

    Number

     

    Description of Document

     

     

     

    10.18**

     

    Amended Advisory Agreement between the registrant and ChemBridges, LLC, dated December 12, 2022.

     

     

     

    10.19**

     

    Amended Executive Employment Agreement between the registrant and Paul Mann effective December 20, 2022.

     

     

     

    10.20**

     

    Acknowledgement of Debt Agreement between ASP Isotopes South Africa (Proprietary) Limited and Klydon (Proprietary) Limited dated November 30, 2022

     

     

     

    10.21**

     

    Deed of Security Agreement between ASP Isotopes South Africa (Proprietary) Limited and Klydon (Proprietary) Limited dated November 30, 2022

     

     

     

    10.22**

     

    Securities Purchase Agreement dated March 14, 2023 (private placement of shares and warrants).

     

     

     

    10.23**

     

    Registration Rights Agreement dated March 14, 2023 (private placement of shares and warrants).

     

     

     

    10.24**

     

    Release Agreement, dated March 23, 2023 between Revere Securities LLC and ASP Isotopes Inc.

     

     

     

    10.25**

     

    Form of Securities Purchase Agreement by and between ASP Isotopes Inc. and the purchasers named therein (October 2023 private placement of shares).

     

     

     

    10.26**

     

    Form of Registration Rights Agreement by and between ASP Isotopes Inc. and the purchasers named therein (October 2023 private placement of shares).

     

     

     

    10.27**

     

    Share Purchase Agreement, dated October 30, 2023, by and between ASP Isotopes Inc., as purchaser, and Nucleonics Imaging Proprietary Limited, as seller, relating to the purchase and sale of ordinary shares of Pet Labs Pharmaceuticals Proprietary Limited.

     

     

     

    10.28**

     

    Convertible Note Purchase Agreement (including Form of Convertible Promissory QLE Note), dated as of February 29, 2024, by and among Quantum Leap Energy LLC and the Purchasers listed therein.

     

     

     

    10.29**

     

    Registration Rights Agreement, dated as of February 29, 2024, by and among Quantum Leap Energy LLC and the Purchasers listed therein.

     

     

     

    10.30+**

     

    Quantum Leap Energy LLC 2024 Equity Incentive Plan.

     

     

     

    21.1**

     

    List of Subsidiaries of the Registrant

     

     

     

    23.1**

     

    Consent of EisnerAmper LLP, independent registered public accounting firm.

     

     

     

    24.1**

     

    Power of Attorney (included as part of the signature page to this report).

     

     
    7

     

     

    Exhibit

     

     

    Number

     

    Description of Document

     

     

     

    31.1*

     

    Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

     

     

     

    31.2*

     

    Certification of Principal Accounting Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

     

     

     

    32.1***

     

    Certification of Principal Executive Officer and Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

     

     

     

    97.1**

     

    Policy Relating to Recovery of Erroneously Awarded Compensation, effective October 2, 2023.

     

     

     

    99.1**

     

    License Agreement, dated as of February 16, 2024, among ASP Isotopes UK Limited, as licensor, and Quantum Leap Energy LLC and Quantum Leap Energy Limited, as licensee.

     

     

     

    99.2**

     

    EPC Services Framework Agreement, dated as of February 16, 2024, between ASP Isotopes Inc. and Quantum Leap Energy LLC.

     

     

     

    101.INS

     

    Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.

     

     

     

    101.SCH

     

    Inline XBRL Taxonomy Extension Schema Document

     

     

     

    101.CAL

     

    Inline XBRL Taxonomy Extension Calculation Linkbase Document

     

     

     

    101.DEF

     

    Inline XBRL Taxonomy Extension Definition Linkbase Document

     

     

     

    101.LAB

     

    Inline XBRL Taxonomy Extension Label Linkbase Document

     

     

     

    101.PRE

     

    Inline XBRL Taxonomy Extension Presentation Linkbase Document

     

     

     

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

    ____________

    *

    Filed herewith.

    **

    Previously filed 

    ***

    Previously furnished

    +

    Management contract or compensatory plan or arrangement.

      

     
    8

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on the 1st day of July, 2024.

     

    ASP Isotopes Inc.

     

     

     

     

     

    By

    /s/ Paul E. Mann

     

     

     

    Paul E. Mann

     

     

     

    Chief Executive Officer and

    Executive Chairman

     

     

     
    9

     

    Get the next $ASPI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASPI

    DatePrice TargetRatingAnalyst
    12/4/2025$13.00Overweight
    Cantor Fitzgerald
    10/4/2024$4.50Buy
    Canaccord Genuity
    12/5/2023$3.25Buy
    H.C. Wainwright
    More analyst ratings

    $ASPI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Kiessling Heather sold $463,840 worth of shares (80,000 units at $5.80), decreasing direct ownership by 10% to 732,500 units (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    12/29/25 9:30:09 PM ET
    $ASPI
    Major Chemicals
    Industrials

    Director Wider Todd was granted 36,548 shares, increasing direct ownership by 5% to 772,247 units (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    12/22/25 9:03:20 PM ET
    $ASPI
    Major Chemicals
    Industrials

    Director Ryan Robert John Andrew was granted 36,548 shares, increasing direct ownership by 6% to 652,222 units (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    12/22/25 9:02:21 PM ET
    $ASPI
    Major Chemicals
    Industrials

    $ASPI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ASP Isotopes Inc. Provides Production Update on the Renergen Helium Project

    This Production Update reports operational progress since April 2025, following bridge loan funding provided by ASP Isotopes Inc. ("ASPI") (prior to the completion of ASPI's acquisition of Renergen), and highlights measurable improvements in drilling execution, gas production, subsurface confidence, and commercial readiness since ASPI involvement. Key highlights include: Investment has augmented existing operational capacity. Management estimates the plant is now processing approximately 60% more gas as a result of improvements and new production wells tied to the plant.Significant improvement in subsurface capability following the engagement of Kinley Exploration:for the first time on the

    1/29/26 7:30:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    ASP Isotopes Closes Acquisition of Renergen

    Combined Company Expected to Become a Global Critical Materials Provider Focused on High-Growth Industries in Isotope and Helium Markets Renergen Expected to Benefit from $750 million of Committed Debt Funding from the U.S. government's Development Finance Corporation (U.S. DFC) and Other Lenders to Expand Helium Plant Production Capacity Combined Company Expected to Target Cross-Sector Applications in Semiconductors, Quantum Computing, and Clean Energy DALLAS, Jan. 07, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) has successfully closed its previously announced acquisition of Renergen Limited, creating a combined company that is focused on the production of critical isotope

    1/7/26 8:30:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    ASP Isotopes Inc. Announces Receipt of Regulatory Approvals for Acquisition of Renergen Limited

    WASHINGTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced that all required regulatory approvals and clearances have been obtained for ASP Isotopes' proposed offer to acquire all of the issued ordinary shares of JSE-listed Renergen Limited ("Renergen"), pursuant to a scheme of arrangement under South African law pursuant to which Renergen shareholders will receive 0.09196 new ASP Isotopes shares for each Renergen share held on the record date (the "Scheme"). Accordingly, a

    12/17/25 9:30:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    $ASPI
    SEC Filings

    View All

    ASP Isotopes Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - ASP Isotopes Inc. (0001921865) (Filer)

    1/30/26 5:00:39 PM ET
    $ASPI
    Major Chemicals
    Industrials

    SEC Form SCHEDULE 13G filed by ASP Isotopes Inc.

    SCHEDULE 13G - ASP Isotopes Inc. (0001921865) (Subject)

    1/30/26 1:28:15 PM ET
    $ASPI
    Major Chemicals
    Industrials

    ASP Isotopes Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ASP Isotopes Inc. (0001921865) (Filer)

    1/29/26 7:30:46 AM ET
    $ASPI
    Major Chemicals
    Industrials

    $ASPI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on ASP Isotopes with a new price target

    Cantor Fitzgerald initiated coverage of ASP Isotopes with a rating of Overweight and set a new price target of $13.00

    12/4/25 8:40:44 AM ET
    $ASPI
    Major Chemicals
    Industrials

    Canaccord Genuity initiated coverage on ASP Isotopes with a new price target

    Canaccord Genuity initiated coverage of ASP Isotopes with a rating of Buy and set a new price target of $4.50

    10/4/24 7:13:36 AM ET
    $ASPI
    Major Chemicals
    Industrials

    H.C. Wainwright initiated coverage on ASP Isotopes with a new price target

    H.C. Wainwright initiated coverage of ASP Isotopes with a rating of Buy and set a new price target of $3.25

    12/5/23 7:36:42 AM ET
    $ASPI
    Major Chemicals
    Industrials

    $ASPI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Ainscow Robert bought 19,992 shares, increasing direct ownership by 2% to 919,992 units (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    7/15/24 10:33:49 AM ET
    $ASPI
    Major Chemicals
    Industrials

    Chief Executive Officer Mann Paul Elliot bought 39,984 shares, increasing direct ownership by 0.69% to 5,845,627 units (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    7/15/24 10:33:33 AM ET
    $ASPI
    Major Chemicals
    Industrials

    Large owner Ak Jensen Investment Management Ltd bought $515,088 worth of shares (161,849 units at $3.18) (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    7/10/24 5:59:47 PM ET
    $ASPI
    Major Chemicals
    Industrials

    $ASPI
    Leadership Updates

    Live Leadership Updates

    View All

    Skyline Announces Change in Strategy, New Management and First Acquisition in Critical Minerals Space

    Hong Kong, Nov. 06, 2025 (GLOBE NEWSWIRE) --  -Appoints Paul Mann Executive Chairman to Lead New Strategic Direction for the Company  -Company makes first Acquisition in Critical Minerals Space Hong Kong, November 6, 2025 (GLOBE NEWSWIRE) – Skyline Builders Group Holding Limited (NASDAQ:SKBL), a Cayman Islands exempted company (the "Company"), today announced a number of strategic changes to the Company's leadership, strategy and corporate headquarters. Appointment of Paul Mann as Executive Chairman Effective January 1, 2026, Paul E. Mann will become Executive Chairman of the Company. Mr. Mann has a 25-year career as an investor and entrepreneur. He is currently the Founder and Executiv

    11/6/25 8:15:00 AM ET
    $ASPI
    $SKBL
    Major Chemicals
    Industrials
    Engineering & Construction
    Consumer Discretionary

    Nuclear Power Industry Veteran Ralph Hunter Joins Board of Directors of ASP Isotopes Inc. and Board of Managers of Quantum Leap Energy LLC

    WASHINGTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced the appointment of Ralph L. Hunter, Jr. to the board of directors of ASP Isotopes and the board of managers of Quantum Leap Energy LLC. Ralph L. Hunter, Jr. has over thirty years' experience in the nuclear power industry in leadership roles spanning strategy, operations, and innovation, and he brings expertise in nuclear technology development and commercialization, energy systems, and market development. Mr. Hun

    9/8/25 8:00:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    ASP Isotopes Issues Letter to Shareholders

    WASHINGTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today released the following letter to shareholders from its Chairman and CEO, Paul Mann. Dear Fellow Shareholder, The past few months have been exciting and highly rewarding as the Company has brought three isotope enrichment facilities into operation. I am delighted to report that the Company has now shipped the first samples of both Ytterbium-176 and Silicon-28 to customers, a major milestone for the Company that should allo

    9/2/25 7:30:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    $ASPI
    Financials

    Live finance-specific insights

    View All

    ASP Isotopes to Provide Quarterly Business Update Call on November 21, 2025 at 8:30am EST

    WASHINGTON, Nov. 17, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) ("ASP Isotopes" or the "Company"), an advanced materials company focused on developing technologies and processes for the production of isotopes for multiple industries, today announced it will hold a quarterly business update conference call and webcast on Friday, November 21, 2025 at 8:30 a.m. (Eastern Time). Conference Call Information To participate in this event, please log on or dial in approximately 5 minutes before the beginning of the call. Webcast Link https://events.q4inc.com/attendee/428149635 Participant Dial-In Details Date: November 21, 2025Time: 8:30 a.m. ESTDial in: USA / International Tol

    11/17/25 4:31:40 PM ET
    $ASPI
    Major Chemicals
    Industrials

    ASP Isotopes Inc. Hosts South African Investors in Advance of Secondary Listing on the Johannesburg Stock Exchange (JSE) and Provides Updates on its Isotope Production Plants

    - ASP Isotopes will host an investor access event on Tuesday, August 26, 2025 at its Pretoria facilities for approximately 30 South African investors. - ASP Isotopes expects to have a secondary listing on the Johannesburg Stock Exchange (JSE) and its common stock is expected to commence trading on the JSE on Wednesday, August 27, 2025. - ASP Isotopes has shipped its first samples of enriched Silicon-28 to a US-based customer and expects to complete the enrichment of the first samples of Ytterbium 176 during August 2025. - ASP Isotopes Management Team will feature on a RedChip Investor call at 4:15 pm EDT on Thursday, August 28, 2025. Ryno Pretorius, CEO of Quantum Leap Energy, and Stefano

    8/26/25 8:00:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    ASP Isotopes Inc. and IsoBio, Inc. Announce Series Seed Funding of IsoBio, Inc. to Advance Innovative Antibody-Isotope Conjugates (AICsTM) For Cancer Treatment

    - IsoBio, Inc. (IsoBio) is a U.S.-based radiotherapeutic development company focused on developing a broad pipeline of mAb-based radioisotope therapeutics, known as antibody-isotope conjugates (AICsTM), targeting both derisked and novel tumor antigens for patients in need of new cancer therapies. - IsoBio has closed its initial Series Seed financing round, raising $5 million from ASP Isotopes Inc. (ASPI). - The strategic collaboration contemplates future manufacturing opportunities for PET Labs (ASPI's nuclear medicine subsidiary). - IsoBio plans to leverage the technology and global manufacturing capabilities developed by ASPI to reduce the uncertainty of isotope supply chain/manufacturi

    7/28/25 8:31:17 AM ET
    $ASPI
    $IMNM
    Major Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASPI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by ASP Isotopes Inc.

    SC 13G - ASP Isotopes Inc. (0001921865) (Subject)

    11/14/24 3:01:19 PM ET
    $ASPI
    Major Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by ASP Isotopes Inc.

    SC 13G/A - ASP Isotopes Inc. (0001921865) (Subject)

    11/7/24 4:15:14 PM ET
    $ASPI
    Major Chemicals
    Industrials

    SEC Form SC 13G filed by ASP Isotopes Inc.

    SC 13G - ASP Isotopes Inc. (0001921865) (Subject)

    11/3/23 4:15:20 PM ET
    $ASPI
    Major Chemicals
    Industrials